Department of Hepatobiliary Surgery, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Yunyan District, Guizhou, 550000, Guiyang, China.
Department of Emergency Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
BMC Cancer. 2023 Jul 6;23(1):635. doi: 10.1186/s12885-023-11112-w.
Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC.
Web of Science, PubMed and Embase were retrieved for qualified literatures on the treatment of advanced HCC with atezolizumab plus bevacizumab until September 1, 2022. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs).
Twenty-three studies, comprising 3168 patients, were enrolled. The pooled OR, CR, and PR rates of the long-term (more than six weeks) therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 26%, 2%, and 23%, respectively. The pooled OR, CR, and PR rates of the short-term (six weeks) therapeutic response evaluated with RECIST were 13%, 0%, and 15%, respectively. The pooled mOS and mPFS were 14.7 months and 6.66 months, respectively. During the treatment, 83% and 30% of patients experienced any grade AEs and grade 3 and above AEs, respectively.
Atezolizumab in combination with bevacizumab showed good efficacy and tolerability in the treatment of advanced HCC. Compared with short-term, non-first-line, and low-dose therapy, atezolizumab plus bevacizumab in long-term, first-line, and standard-dose treatment for advanced HCC showed a better tumor response rate.
阿替利珠单抗联合贝伐珠单抗于 2020 年获批用于治疗晚期肝细胞癌（HCC）。本研究旨在评估该联合方案治疗晚期 HCC 的疗效和耐受性。
检索了截至 2022 年 9 月 1 日在 Web of Science、PubMed 和 Embase 上发表的关于阿替利珠单抗联合贝伐珠单抗治疗晚期 HCC 的合格文献。主要结局指标包括总缓解率（OR）、完全缓解率（CR）、部分缓解率（PR）、中位总生存期（mOS）、中位无进展生存期（mPFS）和不良事件（AEs）。
共纳入 23 项研究，共计 3168 例患者。根据实体瘤疗效评价标准（RECIST），长期（超过 6 周）治疗应答的 OR、CR 和 PR 率分别为 26%、2%和 23%。短期（6 周）治疗应答的 OR、CR 和 PR 率分别为 13%、0%和 15%。mOS 和 mPFS 分别为 14.7 个月和 6.66 个月。治疗期间，83%和 30%的患者分别发生任何级别 AEs 和 3 级及以上 AEs。
阿替利珠单抗联合贝伐珠单抗治疗晚期 HCC 具有良好的疗效和耐受性。与短期、非一线和低剂量治疗相比，阿替利珠单抗联合贝伐珠单抗在晚期 HCC 的长期、一线和标准剂量治疗中显示出更好的肿瘤应答率。
